Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
22 hedge funds and large institutions have $6.44M invested in Timber Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
16% more funds holding
Funds holding: 19 → 22 (+3)
14% less capital invested
Capital invested by funds: $7.5M → $6.44M (-$1.06M)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$80.9K |
| 2 |
Goldman Sachs
New York
|
+$31.8K |
| 3 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
+$8.67K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.67K |
| 5 |
HF
HRT Financial
New York
|
+$5.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$92.5K |
| 2 |
Barclays
London,
United Kingdom
|
-$40.5K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$11K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.78K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.89K |
TMBR Hedge Fund Activity: Q3 2018 in Review
22 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q3 2018, worth a combined $6.44M — down 14% from $7.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TMBR positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, adding an estimated $80.9K. The largest seller was Virtu Financial, cutting an estimated $92.5K.
- 22 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q3 2018, up from 19 in Q2 2018.
- Funds reported $6.44M of Timber Pharmaceuticals, Inc. stock for Q3 2018, down 14% quarter-over-quarter.
- 5 funds opened new Timber Pharmaceuticals, Inc. positions in Q3 2018 and 2 closed out, a net change of +3 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q3 2018 was Millennium Management, an estimated $80.9K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q3 2018 was Virtu Financial, an estimated $92.5K sold.
Based on aggregated 13F filings for Q3 2018.